291 related articles for article (PubMed ID: 18297706)
1. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs.
Perno CF; Moyle G; Tsoukas C; Ratanasuwan W; Gatell J; Schechter M
J Med Virol; 2008 Apr; 80(4):565-76. PubMed ID: 18297706
[TBL] [Abstract][Full Text] [Related]
2. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
Joly V; Yeni P
Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
[TBL] [Abstract][Full Text] [Related]
3. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents.
Adams J; Patel N; Mankaryous N; Tadros M; Miller CD
Ann Pharmacother; 2010 Jan; 44(1):157-65. PubMed ID: 19996323
[TBL] [Abstract][Full Text] [Related]
4. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
[TBL] [Abstract][Full Text] [Related]
5. New developments in HIV drug resistance.
Cane PA
J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i37-40. PubMed ID: 19675018
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral therapy and resistance to antiretroviral drugs.
Lange JM; van Leeuwen R
Ethiop Med J; 2002 Apr; 40 Suppl 1():51-75. PubMed ID: 12802831
[TBL] [Abstract][Full Text] [Related]
7. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
8. Drug-resistant human immunodefiency virus.
Kozal MJ
Clin Microbiol Infect; 2009 Jan; 15 Suppl 1():69-73. PubMed ID: 19220361
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis of human immunodeficiency virus drug resistance: an update.
Menéndez-Arias L
Antiviral Res; 2010 Jan; 85(1):210-31. PubMed ID: 19616029
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
[TBL] [Abstract][Full Text] [Related]
11. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
[TBL] [Abstract][Full Text] [Related]
12. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
Hirsch MS; Günthard HF; Schapiro JM; Brun-Vézinet F; Clotet B; Hammer SM; Johnson VA; Kuritzkes DR; Mellors JW; Pillay D; Yeni PG; Jacobsen DM; Richman DD
Clin Infect Dis; 2008 Jul; 47(2):266-85. PubMed ID: 18549313
[TBL] [Abstract][Full Text] [Related]
14. [Development of new reverse transcriptase inhibitors].
Kodama E
Nihon Rinsho; 2002 Apr; 60(4):775-9. PubMed ID: 11968787
[TBL] [Abstract][Full Text] [Related]
15. Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco.
Smith RJ; Okano JT; Kahn JS; Bodine EN; Blower S
Science; 2010 Feb; 327(5966):697-701. PubMed ID: 20075214
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance. Navigating resistance pathways.
Kuritzkes D
AIDS Read; 2002 Sep; 12(9):395-400, 407. PubMed ID: 12402803
[TBL] [Abstract][Full Text] [Related]
17. Impact of resistance to antiretroviral therapy in the minority community.
Rodriguez AE; Campo RE; Gathe JC; Kwakwa HA
AIDS Read; 2004 Oct; 14(10 Suppl):S9-11. PubMed ID: 15497217
[TBL] [Abstract][Full Text] [Related]
18. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
Cuzin L; Allavena C; Morlat P; Dellamonica P
AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance: a clinical approach.
Yazdanpanah Y
Curr Opin HIV AIDS; 2009 Nov; 4(6):499-506. PubMed ID: 20048717
[TBL] [Abstract][Full Text] [Related]
20. Understanding transmitted HIV resistance through the experience in the USA.
Taiwo B
Int J Infect Dis; 2009 Sep; 13(5):552-9. PubMed ID: 19136289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
